Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

被引：1

作者：

Lavie, David ^{[1
]}

Timmerman, John ^{[2
]}

Garcia-Sanz, Ramon ^{[3
]}

Kim, Won Seog ^{[4
]}

Kim, Tae Min ^{[5
]}

Avigdor, Abraham ^{[6
]}

Dierickx, Daan ^{[7
]}

Jagadeesh, Deepa ^{[8
]}

Molin, Daniel L. ^{[9
]}

Ozcan, Muhit ^{[10
]}

Sevindik, Omur Gokmen ^{[11
]}

Saeed, Hayder ^{[12
]}

Sidi, Yulia ^{[13
]}

Pillai, Pallavi ^{[13
]}

Marinello, Patricia ^{[13
]}

Herrera, Alex F. ^{[14
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[9] Uppsala Univ, Uppsala, Sweden

[10] Ankara Univ, Sch Med, Hematol Dept, Ankara, Turkiye

[11] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Merck & Co Inc, Rahway, NJ 07065 USA

[14] City Hope Natl Med Ctr, Duarte, CA USA

来源：

关键词：

D O I：

10.1182/blood-2023-182119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5